Impact of Peri-Transplant Rituximab and Host/Donor Fc Receptor Polymorphisms for Patients with Relapsed or Refractory CD20+ B-Cell Malignancies
We previously reported results of allogeneic hematopoietic cell transplantation (HCT) in 93 older or medically unfit patients with non-Hodgkin's lymphoma (NHL) or chronic lymphocytic lymphoma (CLL) after conditioning with fludarabine (FLU) and 2-3 Gy total body irradiation (TBI). Three-year survival ranged from 45% to 52% depending on the underlying histology and disease stage. The major complication in those studies was disease relapse (24% at 1 year).The current prospective study in 63 NHL patients tested the hypothesis that disease relapse could be reduced, and overall survival (OS) improved, by peri-transplant rituximab (RTX).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Noa Granot, Andrew Rezvani, Barry E. Storer, Barbara S. Pender, Brenda M. Sandmaier, Rainer Storb, David G. Maloney Tags: 338 Source Type: research
More News: Biology | Cancer & Oncology | Hematology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan | Study | Transplants